Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Identifying individuals with DDX41 germline predisposition syndrome

Catherine Levy, Jennie Vagher, Anthony Pomicter et al. Nov 03, 2025 pp. 6745-6745 10.1182/blood-2025-6745

Abstract Background: Deleterious DDX41 germ line variants cause a predisposition syndrome (DDX41-GPS) that increases the risk of myeloid neo...

Efficacy of CAR-T cell therapy in chronic lymphocytic leukemia: A meta-analysis

Jaison Lawrence Alexander Santhi, Charan Vegivinti, Hassan Ali et al. Nov 03, 2025 pp. 2740-2740 10.1182/blood-2025-2740

Abstract INTRODUCTION: Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the adult population in...

Targeting B- and T-cell lymphomas with anti-CXCR5 CAR T cell therapy

Jinsheng Weng, Eunyoung Lee, Federico Mario Aletti et al. Nov 03, 2025 pp. 3709-3709 10.1182/blood-2025-3709

Abstract Chimeric antigen receptor (CAR) T cell therapy has shown unprecedented efficacy in B-cell leukemias and lymphomas. However, &gt...

Oxidative stress and hemoglobin-c denaturation drive hemoglobin SC pathophysiology and can be ameliorated by antioxidants and hydroxyurea

Tahereh Setayesh, Anifat Tijani, Harsimran Kaur et al. Nov 03, 2025 pp. 7-7 10.1182/blood-2025-7

Abstract Background: Compound heterozygous Hemoglobin SC (HbSC) disease, historically considered a mild form of sickle cell disease, is now...

Clinically relevant bleeding and heavy menstrual bleeding among patients <21 years old with provoked VTE: Findings from the multinational kids-DOTT trial

John Fargo, Maua Alleyne, Ernest Amankwah et al. Nov 03, 2025 pp. 316-316 10.1182/blood-2025-316

Abstract Introduction Clinically relevant bleeding (CRB) remains an adverse outcome of anticoagulation for treatment of...

Monocarboxylate transporter 1 deficient donor T cells rewire metabolism and ameliorate aGVHD lethality

Eun Ko, Asim Saha, Cameron McDonald-Hyman et al. Nov 03, 2025 pp. 5867-5867 10.1182/blood-2025-5867

Abstract Introduction Allogeneic hematopoietic stem cell transplantation is limited by complications, including acute gr...

A prospective, single-arm, multicenter clinical study on the efficacy and safety of romiplostim N01 in acclerating platelet engraftment after autologous hematopoietic stem cell transplantation

Baoquan Song, Yulan Zhou, Mingxing Zhong et al. Nov 03, 2025 pp. 8234-8234 10.1182/blood-2025-8234

Abstract Background and Significance: Autologous hematopoietic stem cell transplantation (ASCT) remains a cornerstone of consolidated or sal...

Predicting mortality in ICU patients with acute leukemias: A new risk score

Jose Manuel Sánchez Albarran, Eduardo Rivero Sigarroa, Maria Roberta Demichelis Gomez Nov 03, 2025 pp. 1543-1543 10.1182/blood-2025-1543

Abstract Introduction: Mortality among patients with hematologic malignancies admitted to the intensive care unit (ICU) ranges from 19% to 8...

CD123-targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr/177Lu-labeled pivekimab

Qichen Hu, Yijing Zhao, Siqi Zhang et al. Nov 03, 2025 pp. 5052-5052 10.1182/blood-2025-5052

Abstract Introduction CD123, the interleukin-3 receptor alpha chain, is highly-expressed on AML blasts and stem cells but less on normal cou...

National landscape of real-world pediatric blinatumomab care delivery in the United States: A report from the Children's Oncology Group

Daniel Zheng, Katelyn Oranges, Subhash Ramakrishnan et al. Nov 03, 2025 pp. 1077-1077 10.1182/blood-2025-1077

Abstract Introduction: The Children's Oncology Group (COG) Trial AALL1731 demonstrated a remarkable reduction in relapse risk with the addit...

Safety and efficacy of ibrutinib as a first line agent for Mantle Cell Lymphoma : A systematic review and meta-analysis

Chandra Kakarala, Yagnapriya Ammakola, Mohammad Arfat Ganiyani et al. Nov 03, 2025 pp. 8101-8101 10.1182/blood-2025-8101

Abstract Background Mantle cell lymphoma (MCL) accounts for approximately 5% of all non-Hodgkin lymphomas and is charact...

Novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies

Haiyang Lü, Su Li, Ang Zhang et al. Nov 03, 2025 pp. 5933-5933 10.1182/blood-2025-5933

Abstract Introduction: Due to the lack of effective therapeutic approaches, refractory/relapse (r/r) aggressive T-cell lymphomas have poor p...

Residual mutations in epigenetic modifiers are associated with poor prognosis and high relapse rate in Acute Myeloid Leukemia

Xin Yan, Chunhua Song, Zheng Ge Nov 03, 2025 pp. 1740-1740 10.1182/blood-2025-1740

Abstract Background Genetic mutations play a crucial role in the development and progression of Acute Myeloid Leukemia (AML), impacting trea...

Successful retreatment of PNH with switch to ravulizumab and add-on danicopan after experiencing breakthrough hemolysis on pegcetacoplan: A case report

Jorge Leguizamo Nov 03, 2025 pp. 6733-6733 10.1182/blood-2025-6733

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder caused by uncontrolled terminal complement act...

Hematopoietic stem cell transplantation with reduced toxicity myeloablative conditioning regimen for children and adults with sickle cell disease: A brazilian single center experience.

Thalita Costa, Luiz Darrigo-Junior, Fabiano Pieroni et al. Nov 03, 2025 pp. 4221-4221 10.1182/blood-2025-4221

Abstract Background: Sickle cell disease (SCD), characterized by vaso-occlusive crises, hemolysis, endothelial damage, and chronic inflammat...

Morbidities in β-thalassemia intermedia across the spectrum of disease severity: A nationwide study in Türkiye

Yesim Aydinok, Zeynep Karakas, Ali Aycicek et al. Nov 03, 2025 pp. 1138-1138 10.1182/blood-2025-1138

Abstract Introduction Accumulated data show that anemia caused by ineffective erythropoiesis and iron overload is linked...

Cost-effectiveness of frontline blinatumomab in children with standard-risk B-cell acute lymphoblastic leukemia in Ontario, Canada

Alexandra Moskalewicz, Giancarlo Di Giuseppe, Petros Pechlivanoglou et al. Nov 03, 2025 pp. 6197-6197 10.1182/blood-2025-6197

Abstract Introduction: The Children's Oncology Group trial AALL1731 (Gupta, NEJM 2025) investigated the addition of the bispecific T-cell en...

Biomarkers of ineffective erythropoiesis in patients with transfusion- dependent thalassemia

Lubna Hamdan, Yasmin Elgammal, Amy Shova et al. Nov 03, 2025 pp. 4684-4684 10.1182/blood-2025-4684

Abstract Introduction Transfusion-dependent thalassemia (TDT) is the prototype of ineffective erythropoiesis (IE)-associ...

Consensus on cytokine release syndrome (CRS) monitoring practices: A Delphi approach

Elisabeth Piault-Louis, Nikki Ow, Laura Cecconi et al. Nov 03, 2025 pp. 4419-4419 10.1182/blood-2025-4419

Abstract Background Cytokine release syndrome (CRS) is a well-known and potentially fatal side effect of T cell redirecting therapy includin...

Transcriptional and splicing dysregulation by U2AF1 mutations contribute to inflammatory and migratory alterations in MDS

Yuki Hodo, Azumi Tomita, Xingxing Qi et al. Nov 03, 2025 pp. 5018-5018 10.1182/blood-2025-5018

Abstract Recent genomic analyses have revealed that mutations in RNA splicing factors—including SF3B1, SRSF2, U2AF1, and ZRSR2—are among the...

CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma

Haifaa Abdulhaq, Linda Lundberg, Anton Belousov et al. Nov 03, 2025 pp. 2559-2559 10.1182/blood-2025-2559

Abstract Background:Glofitamab is a CD20xCD3 T-cell engaging bispecific antibody with a novel 2:1 (CD20:CD3) format, which redirects T cells...

Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States

Farrukh Awan, Nadine Zawadzki, Anna Teschemaker et al. Nov 03, 2025 pp. 2627-2627 10.1182/blood-2025-2627

Abstract INTRODUCTION: Chronic lymphocytic leukemia (CLL) has seen significant therapeutic advances with targeted Bruton's tyrosine kinase (...

MSC affect the sensitivity of CML cells to TKIs through mitochondrial transfered via tunneling nanotubes

Zhechen Miao, Qiang Wang, Qifa Liu Nov 03, 2025 pp. 6758-6758 10.1182/blood-2025-6758

Abstract Tyrosine kinase inhibitors (TKIs) are highly effective in treating chronic myeloid leukemia (CML), but drug resistance remains a si...

Serum cholesterol levels define an inverted u-shaped relationship with PBSC mobilization and immune balance in healthy donors

Ningning Zhu, Jingjing Liu, Nanxi Dong et al. Nov 03, 2025 pp. 7613-7613 10.1182/blood-2025-7613

Abstract Background: Peripheral blood stem cell (PBSC) mobilization with granulocyte colony-stimulating factor (G-CSF) is the standard appro...

Pre-HCT creatinine defines sex-specific risk for severe TMA after allogeneic transplantation: A report from the MIDAS consortium.

Theresa Hahn, Nelli Bejanyan, Qiuhong Zhao et al. Nov 03, 2025 pp. 2429-2429 10.1182/blood-2025-2429

Abstract INTRODUCTION: Severe transplant-associated thrombotic microangiopathy (TMA) is a serious complication of allogeneic hematopoietic c...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page